Substituted pyrimidines as cyclin-dependent kinase inhibitors
The present invention discloses a nitrogen-containing fused heterocyclic compound, as well as a preparation method, intermediate, composition and application thereof. The nitrogen-containing fused heterocyclic compound of the present invention as represented by formula (I), as well as the pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, metabolite or drug precursor thereof, exhibit a high selectivity and a high inhibitory activity with respect to CDK4 and CDK6 at a molecular level, an excellent inhibitory activity with respect to breast cancer cells at a cellular level, and significant inhibition of tumor cell proliferation associated with cyclin-dependent kinase activity at an animal level. The invention also exhibits a good stability with respect to human or mouse liver microsomes without significant inhibition of metabolic enzymes, good in vivo absorption in mice and rats, a high bioavailability and good druggability.
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.
2. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a compound according to claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.
3. A method for inhibiting cyclin-dependent kinase activity in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.
4. A method for inhibiting tumor cells in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.